• 1
    Rodel C, Grabenbauer GG, Kuhn R et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20: 306171.
  • 2
    Shipley WU, Kaufman DS, Tester WJ, Pilepich MV, Sandler HM. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer 2003; 97: 21159.
  • 3
    Shipley WU, Winter KA, Kaufman DS et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998; 16: 357683.
  • 4
    Tester W, Caplan R, Heaney J et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996; 14: 11926.
  • 5
    Kachnic LA, Kaufman DS, Heney NM et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997; 15: 10229.
  • 6
    Dunst J, Rodel C, Zietman A, Schrott KM, Sauer R, Shipley WU. Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy. Semin Surg Oncol 2001; 20: 2432.
  • 7
    Takata R, Katagiri T, Kanehira M et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci 2007; 98: 1137.
  • 8
    Jin S, Levine AJ. The p53 functional circuit. J Cell Sci 2001; 114: 413940.
  • 9
    Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003; 13: 4958.
  • 10
    Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol 2003; 169: 121928.
  • 11
    Sakano S, Matsumoto H, Yamamoto Y et al. Association between DNA repair gene polymorphisms and p53 alterations in Japanese patients with muscle-invasive bladder cancer. Pathobiology 2006; 73: 295303.
  • 12
    Lu ML, Wikman F, Orntoft TF et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res 2002; 8: 1719.
  • 13
    Marin MC, Jost CA, Brooks LA et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000; 25: 4754.
  • 14
    Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19: 1092100.
  • 15
    Baptiste N, Friedlander P, Chen X, Prives C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene 2002; 21: 921.
  • 16
    Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33: 35765.
  • 17
    Bond GL, Hu W, Bond EE et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591602.
  • 18
    Bond GL, Hirshfield KM, Kirchhoff T et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006; 66: 510410.
  • 19
    Han JY, Lee GK, Jang DH, Lee SY, Lee JS. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 2008; 113: 799807.
  • 20
    Galic V, Willner J, Wollan M et al. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer 2007; 46: 23947.
  • 21
    Tu HF, Chen HW, Kao SY, Lin SC, Liu CJ, Chang KW. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiother Oncol 2008; 87: 24352.
  • 22
    Horikawa Y, Nadaoka J, Saito M et al. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep 2008; 20: 4955.
  • 23
    Sanchez-Carbayo M, Socci ND, Kirchoff T et al. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. Clin Cancer Res 2007; 13: 321520.
  • 24
    Shipley WU, Prout GR Jr., Einstein AB et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 1987; 258: 9315.
  • 25
    Matsumoto H, Matsuyama H, Fukunaga K, Yoshihiro S, Wada T, Naito K. Allelic imbalance at 1p36 may predict prognosis of chemoradiation therapy for bladder preservation in patients with invasive bladder cancer. Br J Cancer 2004; 91: 102531.
  • 26
    Sakano S, Wada T, Matsumoto H et al. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer 2006; 95: 56170.
  • 27
    Xu Y, Yao L, Ouyang T et al. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 2005; 11: 732833.
  • 28
    Sotamaa K, Liyanarachchi S, Mecklin JP et al. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 2005; 11: 68404.
  • 29
    Ko JL, Cheng YW, Chang SL, Su JM, Chen CY, Lee H. MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer. Int J Cancer 2000; 89: 26570.
  • 30
    Tanner B, Hengstler JG, Laubscher S et al. mdm 2 mRNA expression is associated with survival in ovarian cancer. Int J Cancer 1997; 74: 43842.
  • 31
    Wu X, Zhao H, Amos CI et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 2002; 94: 68190.
  • 32
    Ribeiro JC, Barnetson AR, Fisher RJ, Mameghan H, Russell PJ. Relationship between radiation response and p53 status in human bladder cancer cells. Int J Radiat Biol 1997; 72: 1120.
  • 33
    Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. p53 and treatment of bladder cancer. Nature 1997; 385: 1235.
  • 34
    Sakano S, Hinoda Y, Okayama N et al. The association of DNA repair gene polymorphisms with the development and progression of renal cell carcinoma. Ann Oncol 2007; 18: 181727.
  • 35
    Sakano S, Kumar R, Larsson P et al. A single-nucleotide polymorphism in the XPG gene, and tumour stage, grade, and clinical course in patients with nonmuscle-invasive neoplasms of the urinary bladder. BJU Int 2006; 97: 84751.
  • 36
    Sasaki M, Sakano S, Okayama N et al. DNA repair gene polymorphisms may be associated with prognosis of upper urinary tract transitional cell carcinoma. Neoplasia 2008; 10: 25565.
  • 37
    Bouska A, Lushnikova T, Plaza S, Eischen CM. Mdm2 promotes genetic instability and transformation independent of p53. Mol Cell Biol 2008; 28: 486274.
  • 38
    Bouska A, Eischen CM. Mdm2 affects genome stability independent of p53. Cancer Res 2009; 69: 1697701.
  • 39
    Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001; 27: 24754.
  • 40
    Cordon-Cardo C, Dalbagni G, Saez GT et al. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 1994; 56: 34753.
  • 41
    Esrig D, Spruck CH III, Nichols PW et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993; 143: 138997.
  • 42
    Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm – general principles. Nat Clin Pract Oncol 2007; 4: 86100.